WINDWARD BIO GROUP AGNew filing
WINDWARD BIO GROUP AG files for an IPO
WINDWARD BIO GROUP AG files for an IPO (October 23, 2026).
WINDWARD BIO GROUP AG develops ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD and atopic dermatitis.
Offering details
- Exchange
- Nasdaq Global Market
- Proposed ticker
- WWB